oxybutynin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| spasmolytics with a papaverine-like action | 2028 | 5633-20-5 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Oxybutynin acts as a competitive antagonist of acetylcholine at post-ganglionic muscarinic receptors, resulting in relaxation of bladder smooth muscle. Oxybutynin is a racemic (50:50) mixture of R- and S-isomers. Antimuscarinic activity resides predominantly in the R-isomer. The R-isomer of oxybutynin shows greater selectivity for the M1 and M3 muscarinic subtypes (predominant in bladder detrusor muscle and parotid gland) compared to the M2 subtype (predominant in cardiac tissue).
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 15 | mg | O |
| 3.90 | mg | TD |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 0.80 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 0.50 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.93 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 6 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 0.85 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 5.10 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.00 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 7.20 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 16, 1975 | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Multiple sclerosis relapse | 222.46 | 10.28 | 219 | 37652 | 41906 | 46606285 |
| Urinary tract infection | 205.04 | 10.28 | 510 | 37361 | 219756 | 46428435 |
| Fall | 186.65 | 10.28 | 638 | 37233 | 328459 | 46319732 |
| Multiple sclerosis | 118.19 | 10.28 | 122 | 37749 | 24669 | 46623522 |
| Urinary incontinence | 110.80 | 10.28 | 126 | 37745 | 28404 | 46619787 |
| Application site erythema | 93.47 | 10.28 | 55 | 37816 | 4849 | 46643342 |
| Dry mouth | 89.28 | 10.28 | 160 | 37711 | 54766 | 46593425 |
| Urine analysis abnormal | 64.51 | 10.28 | 41 | 37830 | 4149 | 46644042 |
| Gait disturbance | 63.87 | 10.28 | 260 | 37611 | 145003 | 46503188 |
| Rheumatoid arthritis | 54.44 | 10.28 | 69 | 37802 | 240146 | 46408045 |
| Balance disorder | 52.17 | 10.28 | 142 | 37729 | 64379 | 46583812 |
| Exposure during pregnancy | 50.03 | 10.28 | 13 | 37858 | 108199 | 46539992 |
| Micturition urgency | 49.54 | 10.28 | 45 | 37826 | 7772 | 46640419 |
| Laboratory test abnormal | 47.03 | 10.28 | 74 | 37797 | 22773 | 46625418 |
| Application site pruritus | 46.70 | 10.28 | 33 | 37838 | 3980 | 46644211 |
| Maternal exposure during pregnancy | 44.30 | 10.28 | 14 | 37857 | 102535 | 46545656 |
| Neurogenic bladder | 41.17 | 10.28 | 27 | 37844 | 2883 | 46645308 |
| Secondary progressive multiple sclerosis | 41.12 | 10.28 | 20 | 37851 | 1200 | 46646991 |
| Bladder disorder | 39.57 | 10.28 | 38 | 37833 | 7040 | 46641151 |
| Pollakiuria | 38.54 | 10.28 | 70 | 37801 | 24191 | 46624000 |
| Hypertonic bladder | 38.00 | 10.28 | 26 | 37845 | 2978 | 46645213 |
| Product adhesion issue | 36.36 | 10.28 | 31 | 37840 | 4924 | 46643267 |
| Systemic lupus erythematosus | 33.85 | 10.28 | 6 | 37865 | 65174 | 46583017 |
| Urine leukocyte esterase positive | 32.20 | 10.28 | 22 | 37849 | 2513 | 46645678 |
| Culture urine positive | 30.75 | 10.28 | 24 | 37847 | 3367 | 46644824 |
| Joint swelling | 30.53 | 10.28 | 55 | 37816 | 166018 | 46482173 |
| Muscular weakness | 30.25 | 10.28 | 151 | 37720 | 91693 | 46556498 |
| Mental status changes | 29.95 | 10.28 | 83 | 37788 | 38005 | 46610186 |
| Incontinence | 29.22 | 10.28 | 38 | 37833 | 9824 | 46638367 |
| White blood cells urine positive | 28.76 | 10.28 | 25 | 37846 | 4075 | 46644116 |
| Confusional state | 28.22 | 10.28 | 224 | 37647 | 159668 | 46488523 |
| Escherichia urinary tract infection | 27.86 | 10.28 | 38 | 37833 | 10285 | 46637906 |
| Malignant neoplasm progression | 27.79 | 10.28 | 9 | 37862 | 64917 | 46583274 |
| Band neutrophil percentage increased | 26.88 | 10.28 | 9 | 37862 | 201 | 46647990 |
| Dysuria | 26.33 | 10.28 | 65 | 37806 | 27768 | 46620423 |
| Monocyte percentage increased | 26.14 | 10.28 | 14 | 37857 | 1029 | 46647162 |
| Febrile neutropenia | 26.08 | 10.28 | 23 | 37848 | 94604 | 46553587 |
| Gait inability | 25.05 | 10.28 | 74 | 37797 | 35129 | 46613062 |
| Off label use | 25.01 | 10.28 | 193 | 37678 | 379648 | 46268543 |
| Application site rash | 25.00 | 10.28 | 19 | 37852 | 2563 | 46645628 |
| Myelocyte percentage increased | 24.53 | 10.28 | 8 | 37863 | 164 | 46648027 |
| Cerebral atrophy | 23.90 | 10.28 | 24 | 37847 | 4692 | 46643499 |
| Bacterial test | 23.84 | 10.28 | 14 | 37857 | 1229 | 46646962 |
| Urinary sediment present | 23.61 | 10.28 | 16 | 37855 | 1804 | 46646387 |
| Synovitis | 23.56 | 10.28 | 10 | 37861 | 61065 | 46587126 |
| Muscle spasticity | 23.46 | 10.28 | 37 | 37834 | 11403 | 46636788 |
| Urine oxalate increased | 23.27 | 10.28 | 8 | 37863 | 194 | 46647997 |
| Abortion spontaneous | 22.70 | 10.28 | 4 | 37867 | 43642 | 46604549 |
| Red blood cells urine positive | 22.66 | 10.28 | 18 | 37853 | 2589 | 46645602 |
| Band neutrophil count increased | 22.59 | 10.28 | 9 | 37862 | 333 | 46647858 |
| Prescription drug used without a prescription | 22.29 | 10.28 | 14 | 37857 | 1388 | 46646803 |
| Cystitis | 22.13 | 10.28 | 80 | 37791 | 42161 | 46606030 |
| Bladder spasm | 21.60 | 10.28 | 14 | 37857 | 1465 | 46646726 |
| Hallucination | 21.58 | 10.28 | 89 | 37782 | 49862 | 46598329 |
| Dysmetropsia | 21.15 | 10.28 | 6 | 37865 | 75 | 46648116 |
| Crystal urine present | 21.09 | 10.28 | 13 | 37858 | 1246 | 46646945 |
| Injection site scar | 21.05 | 10.28 | 11 | 37860 | 769 | 46647422 |
| Treatment failure | 20.77 | 10.28 | 27 | 37844 | 93060 | 46555131 |
| Urinary retention | 20.69 | 10.28 | 57 | 37814 | 26004 | 46622187 |
| Retinal depigmentation | 20.67 | 10.28 | 8 | 37863 | 274 | 46647917 |
| Hallucination, visual | 20.48 | 10.28 | 45 | 37826 | 17828 | 46630363 |
| Food refusal | 20.42 | 10.28 | 8 | 37863 | 283 | 46647908 |
| Specific gravity urine decreased | 20.31 | 10.28 | 9 | 37862 | 436 | 46647755 |
| Neutropenia | 20.09 | 10.28 | 55 | 37816 | 143149 | 46505042 |
| Asthenia | 20.06 | 10.28 | 359 | 37512 | 310716 | 46337475 |
| Lymphocyte percentage decreased | 20.04 | 10.28 | 17 | 37854 | 2682 | 46645509 |
| Depression | 19.77 | 10.28 | 218 | 37653 | 169886 | 46478305 |
| Psychotic symptom | 19.46 | 10.28 | 11 | 37860 | 899 | 46647292 |
| Toxicity to various agents | 19.42 | 10.28 | 97 | 37774 | 211669 | 46436522 |
| Urinary tract infection bacterial | 18.95 | 10.28 | 20 | 37851 | 4145 | 46644046 |
| Myelocyte count increased | 18.80 | 10.28 | 8 | 37863 | 351 | 46647840 |
| Dementia | 18.73 | 10.28 | 39 | 37832 | 14891 | 46633300 |
| Amnesia | 18.64 | 10.28 | 75 | 37796 | 41556 | 46606635 |
| Lymphocyte count decreased | 18.40 | 10.28 | 54 | 37817 | 25535 | 46622656 |
| Thrombocytopenia | 18.22 | 10.28 | 48 | 37823 | 126533 | 46521658 |
| Drug intolerance | 18.10 | 10.28 | 60 | 37811 | 146989 | 46501202 |
| Hepatic enzyme increased | 17.97 | 10.28 | 24 | 37847 | 81763 | 46566428 |
| Chronic papillomatous dermatitis | 17.81 | 10.28 | 5 | 37866 | 60 | 46648131 |
| Head injury | 17.73 | 10.28 | 52 | 37819 | 24584 | 46623607 |
| Product administered at inappropriate site | 17.67 | 10.28 | 15 | 37856 | 2368 | 46645823 |
| Nocturia | 17.38 | 10.28 | 25 | 37846 | 7107 | 46641084 |
| Application site vesicles | 16.95 | 10.28 | 12 | 37859 | 1452 | 46646739 |
| Lagophthalmos | 16.87 | 10.28 | 7 | 37864 | 288 | 46647903 |
| Drug abuse | 16.77 | 10.28 | 16 | 37855 | 63392 | 46584799 |
| Application site irritation | 16.76 | 10.28 | 13 | 37858 | 1806 | 46646385 |
| Dermatitis contact | 16.28 | 10.28 | 26 | 37845 | 8097 | 46640094 |
| Injection related reaction | 15.99 | 10.28 | 8 | 37863 | 510 | 46647681 |
| Glossodynia | 15.97 | 10.28 | 8 | 37863 | 44365 | 46603826 |
| Lymphopenia | 15.85 | 10.28 | 37 | 37834 | 15256 | 46632935 |
| Abdominal discomfort | 15.78 | 10.28 | 66 | 37805 | 151099 | 46497092 |
| Urine abnormality | 15.72 | 10.28 | 21 | 37850 | 5573 | 46642618 |
| Infusion related reaction | 15.64 | 10.28 | 37 | 37834 | 101171 | 46547020 |
| Porphyria acute | 15.13 | 10.28 | 7 | 37864 | 375 | 46647816 |
| Urinary tract infection pseudomonal | 14.78 | 10.28 | 9 | 37862 | 844 | 46647347 |
| Anaphylactic reaction | 14.52 | 10.28 | 13 | 37858 | 53099 | 46595092 |
| Urine odour abnormal | 14.51 | 10.28 | 19 | 37852 | 4943 | 46643248 |
| Thyroglobulin increased | 14.49 | 10.28 | 4 | 37867 | 45 | 46648146 |
| Neutrophil percentage increased | 14.22 | 10.28 | 14 | 37857 | 2673 | 46645518 |
| Skin irritation | 14.16 | 10.28 | 23 | 37848 | 7264 | 46640927 |
| Resting tremor | 13.95 | 10.28 | 8 | 37863 | 672 | 46647519 |
| Decubitus ulcer | 13.78 | 10.28 | 27 | 37844 | 9871 | 46638320 |
| Pyelonephritis | 13.62 | 10.28 | 35 | 37836 | 15322 | 46632869 |
| Product complaint | 13.34 | 10.28 | 30 | 37841 | 12071 | 46636120 |
| Dizziness | 13.08 | 10.28 | 365 | 37506 | 340049 | 46308142 |
| Stress urinary incontinence | 13.05 | 10.28 | 12 | 37859 | 2104 | 46646087 |
| Pregnancy | 13.04 | 10.28 | 3 | 37868 | 27134 | 46621057 |
| Arthralgia | 12.93 | 10.28 | 213 | 37658 | 364390 | 46283801 |
| Bone marrow failure | 12.89 | 10.28 | 4 | 37867 | 29665 | 46618526 |
| Impaired self-care | 12.85 | 10.28 | 11 | 37860 | 1757 | 46646434 |
| Open fracture | 12.84 | 10.28 | 6 | 37865 | 329 | 46647862 |
| Hepatic function abnormal | 12.70 | 10.28 | 6 | 37865 | 34415 | 46613776 |
| Repetitive strain injury | 12.60 | 10.28 | 5 | 37866 | 183 | 46648008 |
| Product closure removal difficult | 12.53 | 10.28 | 3 | 37868 | 18 | 46648173 |
| Intentional overdose | 12.38 | 10.28 | 21 | 37850 | 64923 | 46583268 |
| Memory impairment | 12.36 | 10.28 | 106 | 37765 | 77231 | 46570960 |
| Prescribed underdose | 12.31 | 10.28 | 29 | 37842 | 12024 | 46636167 |
| Nephrolithiasis | 12.07 | 10.28 | 56 | 37815 | 32995 | 46615196 |
| Drug withdrawal syndrome neonatal | 12.02 | 10.28 | 11 | 37860 | 1917 | 46646274 |
| Walking aid user | 11.95 | 10.28 | 17 | 37854 | 4783 | 46643408 |
| Nausea | 11.95 | 10.28 | 447 | 37424 | 687007 | 45961184 |
| Body height decreased | 11.86 | 10.28 | 25 | 37846 | 9627 | 46638564 |
| Mixed incontinence | 11.75 | 10.28 | 4 | 37867 | 94 | 46648097 |
| Interstitial lung disease | 11.67 | 10.28 | 16 | 37855 | 53933 | 46594258 |
| Incision site pruritus | 11.67 | 10.28 | 3 | 37868 | 25 | 46648166 |
| Hallucinations, mixed | 11.67 | 10.28 | 15 | 37856 | 3834 | 46644357 |
| Vertigo | 11.51 | 10.28 | 77 | 37794 | 51971 | 46596220 |
| Haemoglobin urine present | 11.47 | 10.28 | 7 | 37864 | 659 | 46647532 |
| Intestinal pseudo-obstruction | 11.46 | 10.28 | 7 | 37864 | 660 | 46647531 |
| Basophil count decreased | 11.34 | 10.28 | 4 | 37867 | 105 | 46648086 |
| Dysarthria | 11.19 | 10.28 | 60 | 37811 | 37438 | 46610753 |
| Klebsiella test positive | 11.14 | 10.28 | 8 | 37863 | 989 | 46647202 |
| Anaemia folate deficiency | 11.13 | 10.28 | 5 | 37866 | 250 | 46647941 |
| Tri-iodothyronine increased | 11.03 | 10.28 | 4 | 37867 | 114 | 46648077 |
| Coordination abnormal | 10.81 | 10.28 | 26 | 37845 | 10923 | 46637268 |
| Urinary tract disorder | 10.54 | 10.28 | 11 | 37860 | 2249 | 46645942 |
| Visual impairment | 10.44 | 10.28 | 91 | 37780 | 66598 | 46581593 |
| Incision site erythema | 10.42 | 10.28 | 5 | 37866 | 291 | 46647900 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Urinary tract infection | 150.68 | 13.02 | 175 | 13246 | 73484 | 29865573 |
| Dry mouth | 82.76 | 13.02 | 74 | 13347 | 22776 | 29916281 |
| Fall | 69.95 | 13.02 | 209 | 13212 | 181663 | 29757394 |
| Multiple sclerosis relapse | 64.51 | 13.02 | 47 | 13374 | 10815 | 29928242 |
| Confusional state | 63.64 | 13.02 | 167 | 13254 | 134667 | 29804390 |
| Multiple sclerosis | 46.72 | 13.02 | 33 | 13388 | 7234 | 29931823 |
| Muscle spasticity | 41.56 | 13.02 | 27 | 13394 | 5161 | 29933896 |
| Disorganised speech | 34.90 | 13.02 | 12 | 13409 | 537 | 29938520 |
| Urinary retention | 30.89 | 13.02 | 54 | 13367 | 32863 | 29906194 |
| Bladder spasm | 26.04 | 13.02 | 11 | 13410 | 867 | 29938190 |
| Daydreaming | 25.01 | 13.02 | 9 | 13412 | 461 | 29938596 |
| Constipation | 24.62 | 13.02 | 108 | 13313 | 112798 | 29826259 |
| Completed suicide | 23.09 | 13.02 | 97 | 13324 | 99395 | 29839662 |
| Hallucination | 21.28 | 13.02 | 59 | 13362 | 49000 | 29890057 |
| Urosepsis | 21.04 | 13.02 | 25 | 13396 | 10707 | 29928350 |
| Syncope | 19.87 | 13.02 | 83 | 13338 | 84820 | 29854237 |
| Urinary incontinence | 18.84 | 13.02 | 30 | 13391 | 16910 | 29922147 |
| Delirium | 18.76 | 13.02 | 50 | 13371 | 40581 | 29898476 |
| Nephrolithiasis | 18.63 | 13.02 | 37 | 13384 | 24773 | 29914284 |
| Pollakiuria | 17.52 | 13.02 | 29 | 13392 | 16877 | 29922180 |
| Gait disturbance | 17.41 | 13.02 | 73 | 13348 | 74704 | 29864353 |
| Interstitial lung disease | 17.41 | 13.02 | 3 | 13418 | 60194 | 29878863 |
| Intestinal pseudo-obstruction | 17.29 | 13.02 | 9 | 13412 | 1137 | 29937920 |
| Dizziness | 17.01 | 13.02 | 147 | 13274 | 194762 | 29744295 |
| Neurogenic bladder | 16.85 | 13.02 | 10 | 13411 | 1629 | 29937428 |
| Decubitus ulcer | 16.70 | 13.02 | 19 | 13402 | 7769 | 29931288 |
| Granulocytopenia | 16.52 | 13.02 | 17 | 13404 | 6209 | 29932848 |
| Cognitive disorder | 16.22 | 13.02 | 34 | 13387 | 23656 | 29915401 |
| Rib hypoplasia | 15.31 | 13.02 | 3 | 13418 | 12 | 29939045 |
| Pulmonary hypoplasia | 14.81 | 13.02 | 6 | 13415 | 425 | 29938632 |
| Amnesia | 14.48 | 13.02 | 33 | 13388 | 24288 | 29914769 |
| Vision blurred | 14.08 | 13.02 | 46 | 13375 | 41770 | 29897287 |
| Implant site erosion | 14.05 | 13.02 | 4 | 13417 | 95 | 29938962 |
| Muscular weakness | 13.94 | 13.02 | 61 | 13360 | 63584 | 29875473 |
| Haematuria | 13.93 | 13.02 | 48 | 13373 | 44786 | 29894271 |
| Tongue haemorrhage | 13.92 | 13.02 | 6 | 13415 | 497 | 29938560 |
| Mental status changes | 13.59 | 13.02 | 42 | 13379 | 37037 | 29902020 |
| Hypertonic bladder | 13.54 | 13.02 | 7 | 13414 | 872 | 29938185 |
| Asthenia | 13.52 | 13.02 | 155 | 13266 | 221135 | 29717922 |
| Abnormal behaviour | 13.34 | 13.02 | 33 | 13388 | 25590 | 29913467 |
| Hepatitis acute | 13.06 | 13.02 | 16 | 13405 | 7067 | 29931990 |
| Bladder catheterisation | 13.06 | 13.02 | 6 | 13415 | 578 | 29938479 |
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | G04BD04 | GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS UROLOGICALS Drugs for urinary frequency and incontinence |
| FDA MoA | N0000000125 | Cholinergic Muscarinic Antagonists |
| FDA EPC | N0000175700 | Cholinergic Muscarinic Antagonist |
| MeSH PA | D018678 | Cholinergic Agents |
| MeSH PA | D018680 | Cholinergic Antagonists |
| MeSH PA | D018727 | Muscarinic Antagonists |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D010276 | Parasympatholytics |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D064804 | Urological Agents |
| CHEBI has role | CHEBI:36333 | local anesthetics |
| CHEBI has role | CHEBI:38215 | calcium channel blockers |
| CHEBI has role | CHEBI:48876 | antimuskarinika |
| CHEBI has role | CHEBI:50370 | parasympatholytics |
| CHEBI has role | CHEBI:51371 | muscle relaxants |
| CHEBI has role | CHEBI:53784 | antispasmodics |
Drug Use (View source of the data)
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Urgent desire to urinate | indication | 75088002 | |
| Urge incontinence of urine | indication | 87557004 | |
| Bladder muscle dysfunction - overactive | indication | 236633002 | |
| Neurogenic bladder | indication | 398064005 | |
| Increased Urinary Frequency | indication | ||
| Sinus tachycardia | contraindication | 11092001 | |
| Severe chronic ulcerative colitis | contraindication | 14311001 | |
| Toxic megacolon | contraindication | 28536002 | DOID:1770 |
| Atony of colon | contraindication | 29479008 | |
| Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Conduction disorder of the heart | contraindication | 44808001 | |
| Chronic heart failure | contraindication | 48447003 | |
| Paralytic ileus | contraindication | 55525008 | DOID:8442 |
| Ulcerative colitis | contraindication | 64766004 | DOID:8577 |
| Hiatal hernia | contraindication | 84089009 | DOID:12642 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Myasthenia gravis | contraindication | 91637004 | DOID:437 |
| Gastrointestinal obstruction | contraindication | 126765001 | |
| Gastroesophageal reflux disease | contraindication | 235595009 | DOID:8534 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Bladder outflow obstruction | contraindication | 236645006 | |
| Benign prostatic hyperplasia | contraindication | 266569009 | |
| Retention of urine | contraindication | 267064002 | |
| Drowsy | contraindication | 271782001 | |
| Gastric retention | contraindication | 307227006 | |
| Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
| Disorder of coronary artery | contraindication | 414024009 | |
| Gastrointestinal hypomotility | contraindication | 421807004 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 7.67 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Muscarinic acetylcholine receptor M1 | GPCR | ANTAGONIST | Ki | 9 | CHEMBL | DRUG LABEL | |||
| Muscarinic acetylcholine receptor M3 | GPCR | ANTAGONIST | Ki | 9.11 | CHEMBL | DRUG LABEL | |||
| 5-hydroxytryptamine receptor 2B | GPCR | Ki | 6.30 | DRUG MATRIX | |||||
| D(3) dopamine receptor | GPCR | Ki | 6.84 | DRUG MATRIX | |||||
| Sodium-dependent dopamine transporter | Transporter | Ki | 7.17 | DRUG MATRIX | |||||
| Cytochrome P450 2C19 | Enzyme | IC50 | 6.22 | DRUG MATRIX | |||||
| Muscarinic acetylcholine receptor M2 | GPCR | ANTAGONIST | Ki | 8.09 | CHEMBL | ||||
| Muscarinic acetylcholine receptor M4 | GPCR | Ki | 8.44 | CHEMBL | |||||
| Sigma non-opioid intracellular receptor 1 | Membrane receptor | Ki | 7.99 | DRUG MATRIX | |||||
| Muscarinic acetylcholine receptor M5 | GPCR | Ki | 7.85 | CHEMBL | |||||
| Sodium-dependent noradrenaline transporter | Transporter | Ki | 5.59 | DRUG MATRIX | |||||
| Membrane-associated progesterone receptor component 1 | Membrane receptor | Ki | 6.09 | DRUG MATRIX | |||||
| Muscarinic acetylcholine receptor M1 | GPCR | Ki | 8.23 | CHEMBL | |||||
| Muscarinic acetylcholine receptor M3 | GPCR | Ki | 9.02 | CHEMBL | |||||
| Muscarinic acetylcholine receptor M2 | GPCR | Ki | 8.16 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4018815 | VUID |
| N0000147118 | NUI |
| D00465 | KEGG_DRUG |
| 1508-65-2 | SECONDARY_CAS_RN |
| 4018815 | VANDF |
| 4019869 | VANDF |
| C0591395 | UMLSCUI |
| CHEBI:7856 | CHEBI |
| CHEMBL1133 | ChEMBL_ID |
| CHEMBL1231 | ChEMBL_ID |
| DB01062 | DRUGBANK_ID |
| C005419 | MESH_SUPPLEMENTAL_RECORD_UI |
| 4634 | PUBCHEM_CID |
| 359 | IUPHAR_LIGAND_ID |
| 1354 | INN_ID |
| K9P6MC7092 | UNII |
| 151651 | RXNORM |
| 180 | MMSL |
| 28244 | MMSL |
| 4610 | MMSL |
| 46359 | MMSL |
| 5214 | MMSL |
| d00328 | MMSL |
| 001768 | NDDF |
| 004715 | NDDF |
| 31815007 | SNOMEDCT_US |
| 35768004 | SNOMEDCT_US |
| 372717000 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| GELNIQUE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0023-5812 | GEL | 100 mg | TRANSDERMAL | NDA | 27 sections |
| GELNIQUE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0023-5861 | GEL | 100 mg | TRANSDERMAL | NDA | 27 sections |
| OXYTROL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0023-6153 | PATCH | 3.90 mg | TRANSDERMAL | NDA | 26 sections |
| Oxytrol for Women | HUMAN OTC DRUG LABEL | 1 | 0023-9637 | PATCH | 3.90 mg | TRANSDERMAL | NDA | 14 sections |
| OXYBUTYNIN CHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0121-0671 | SYRUP | 5 mg | ORAL | ANDA | 18 sections |
| Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0603-4975 | TABLET | 5 mg | ORAL | ANDA | 24 sections |
| Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-3512 | TABLET | 5 mg | ORAL | ANDA | 21 sections |
| oxybutynin chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-7521 | TABLET, EXTENDED RELEASE | 15 mg | ORAL | NDA | 23 sections |
| oxybutynin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8219 | TABLET, FILM COATED, EXTENDED RELEASE | 5 mg | ORAL | ANDA | 24 sections |
| Oxybutynin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8220 | TABLET, FILM COATED, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 24 sections |
| Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0832-0038 | TABLET | 5 mg | ORAL | ANDA | 23 sections |
| Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-2821 | TABLET | 5 mg | ORAL | ANDA | 21 sections |
| Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6570 | TABLET, EXTENDED RELEASE | 5 mg | ORAL | ANDA | 25 sections |
| Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-609 | TABLET, EXTENDED RELEASE | 5 mg | ORAL | ANDA | 29 sections |
| Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-610 | TABLET, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 29 sections |
| Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-611 | TABLET, EXTENDED RELEASE | 15 mg | ORAL | ANDA | 29 sections |
| Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-640 | TABLET | 5 mg | ORAL | ANDA | 23 sections |
| Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-518 | TABLET | 5 mg | ORAL | ANDA | 24 sections |
| Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-559 | TABLET | 5 mg | ORAL | ANDA | 21 sections |
| Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10702-201 | TABLET | 5 mg | ORAL | ANDA | 22 sections |
| Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 14539-653 | TABLET | 5 mg | ORAL | ANDA | 13 sections |
| oxybutynin chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-317 | TABLET, EXTENDED RELEASE | 5 mg | ORAL | ANDA | 26 sections |
| oxybutynin chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-318 | TABLET, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 26 sections |
| oxybutynin chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-319 | TABLET, EXTENDED RELEASE | 15 mg | ORAL | ANDA | 26 sections |
| Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17856-0092 | SYRUP | 5 mg | ORAL | ANDA | 17 sections |
| Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17856-0149 | SYRUP | 5 mg | ORAL | ANDA | 21 sections |
| Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17856-1491 | SOLUTION | 5 mg | ORAL | ANDA | 23 sections |
| Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-406 | TABLET | 5 mg | ORAL | ANDA | 23 sections |
| Oxybutynin Chloride | Human Prescription Drug Label | 1 | 27241-155 | TABLET, EXTENDED RELEASE | 5 mg | ORAL | ANDA | 25 sections |
| Oxybutynin Chloride | Human Prescription Drug Label | 1 | 27241-156 | TABLET, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 25 sections |